ACP3 and prostate cancer: Sipuleucel-T (Provenge) is an autologous cellular immunotherapy and was the first FDA-approved cancer vaccine for mCRPC; it is primarily indicated for asymptomatic or minimally symptomatic patients, working by stimulating the patient’s immune system to target prostatic acid phosphatase (PAP), a prostate cancer-associated antigen [122].